Zavante Therapeutics
Injectable antibiotic for multi-drug resistant bacterial infections
About Zavante Therapeutics
Zavante Therapeutics, Inc. was a privately-held, late clinical-stage biopharmaceutical company founded in 2015 in San Diego, California. The company focused on developing and commercializing novel antibacterial agents to treat serious infections, particularly those caused by multi-drug resistant (MDR) pathogens in hospitalized patients.
The company's lead product candidate was an intravenous formulation of fosfomycin, initially known as ZTI-01 and later branded as ZOLYD™ and CONTEPO™. This first-in-class epoxide antibiotic was developed to provide a new treatment option for complicated urinary tract infections (cUTIs), including acute pyelonephritis, and other serious infections caused by MDR Gram-negative and Gram-positive bacteria. The intravenous version of fosfomycin, which has been used outside the U.S. for over 40 years, was repurposed by Zavante with a new dosing approach to optimize its effectiveness for the U.S. market. The FDA granted the drug Qualified Infectious Disease Product (QIDP) and Fast Track designations.
The company was founded by Ted Schroeder, who also served as President and CEO. Prior to Zavante, Schroeder co-founded Cadence Pharmaceuticals, where he also served as President and CEO until its acquisition in 2014. In July 2018, Zavante Therapeutics was acquired by Nabriva Therapeutics plc in a stock deal. The acquisition was valued at approximately $27 million upfront, with former Zavante stockholders eligible for up to $97.5 million in additional payments based on regulatory and commercial milestones. Following the acquisition, Ted Schroeder was appointed CEO of Nabriva Therapeutics.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jul 2018 | $0 | — | Nabriva Therapeutics | — |
| DEBTDebt | Sep 2016 | $10M | — | Square 1 Bank | — |
Growth signals
Latest recorded traffic for Zavante Therapeutics is 10 monthly website visits, down 98.3% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Zavante Therapeutics in the San Diego ecosystem
The Zavante Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Square 1 Bank
Frazier Healthcare Partners
Longitude Capital
Other known investors1 additional known investor
Nabriva Therapeutics
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zavante Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zavante Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









